NOD1 and NOD2: Molecular targets in prevention and treatment of infectious diseases

被引：22
|
作者：
Pashenkov, Mikhail V. [1 ]
Dagil, Yulia A. [1 ]
Pinegin, Boris V. [1 ]
机构：
[1] Fed Med Biol Agcy, Natl Res Ctr, Inst Immunol, Lab Clin Immunol, Moscow, Russia
来源：
INTERNATIONAL IMMUNOPHARMACOLOGY | 2018年 / 54卷
基金：
俄罗斯科学基金会;
关键词：
NOD1; NOD2; Muropeptides; Infectious diseases; Innate immunity; Mucosal immunity; TOLL-LIKE RECEPTOR; NF-KAPPA-B; MESO-DIAMINOPIMELIC ACID; INNATE IMMUNE-RESPONSES; BACTERIAL MURAMYL DIPEPTIDE; INTESTINAL EPITHELIAL-CELLS; OLIGOMERIZATION DOMAIN 1; MYCOBACTERIUM-TUBERCULOSIS INFECTION; AUREUS-DERIVED PEPTIDOGLYCAN; HUMAN MONOCYTIC CELLS;
D O I：
10.1016/j.intimp.2017.11.036
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Nucleotide-binding oligomerization domain (NOD) 1 and NOD2 are pattern-recognition receptors responsible for sensing fragments of bacterial peptidoglycan known as muropeptides. Stimulation of innate immunity by systemic or local administration of NOD1 and NOD2 agonists is an attractive means to prevent and treat infectious diseases. In this review, we discuss novel data concerning structural features of selective and nonselective (dual) NOD1 and NOD2 agonists, main signaling pathways and biological effects induced by NOD1 and NOD2 stimulation, including induction of pro-inflammatory cytokines, type I interferons and antimicrobial peptides, induction of autophagy, alterations of metabolism. We also discuss interactions between NOD1/NOD2 and Toll-like receptor agonists in terms of synergy and cross-tolerance. Finally, we review available animal data on the role of NOD1 and NOD2 in protection against infections, and discuss how these data could be applied in human infectious diseases.
引用
收藏
页码：385 / 400
页数：16
相关论文
共 50 条
  • [1] NOD1 and NOD2 in inflammatory and infectious diseases
    Trindade, Bruno C.
    Chen, Grace Y.
    [J]. IMMUNOLOGICAL REVIEWS, 2020, 297 (01) : 139 - 161
  • [2] Signalling pathways and molecular interactions of NOD1 and NOD2
    Warren Strober
    Peter J. Murray
    Atsushi Kitani
    Tomohiro Watanabe
    [J]. Nature Reviews Immunology, 2006, 6 : 9 - 20
  • [3] Signalling pathways and molecular interactions of NOD1 and NOD2
    Strober, W
    Murray, PJ
    Kitani, A
    Watanabe, T
    [J]. NATURE REVIEWS IMMUNOLOGY, 2006, 6 (01) : 9 - 20
  • [4] Pathway Selection by Nod1 and Nod2
    Heul, A. Ver
    Ramaswamy, S.
    Piper, R.
    [J]. MOLECULAR BIOLOGY OF THE CELL, 2011, 22
  • [5] Peptidoglycan molecular requirements allowing detection by Nod1 and Nod2
    Girardin, SE
    Travassos, LH
    Hervé, M
    Blanot, D
    Boneca, IG
    Philpott, DJ
    Sansonetti, PJ
    Mengin-Lecreulx, D
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (43) : 41702 - 41708
  • [6] NOD1 and NOD2 signaling in infection and inflammation
    Moreira, Lilian O.
    Zamboni, Dario S.
    [J]. FRONTIERS IN IMMUNOLOGY, 2012, 3
  • [7] Analgesic effects of NOD1 and NOD2 agonists
    Sato, Tadasu
    Shimauchi, Hidetoshi
    Endo, Yasuo
    Takada, Haruhiko
    [J]. INTERFACE ORAL HEALTH SCIENCE 2009, 2010, : 217 - +
  • [8] NOD1 and NOD2 in inflammation, immunity and disease
    Mukherjee, Tapas
    Hovingh, Elise Sofie
    Foerster, Elisabeth G.
    Abdel-Nour, Mena
    Philpott, Dana J.
    Girardin, Stephen E.
    [J]. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2019, 670 : 69 - 81
  • [9] NOD1 and NOD2: Beyond Peptidoglycan Sensing
    Keestra-Gounder, A. Marijke
    Tsolis, Renee M.
    [J]. TRENDS IN IMMUNOLOGY, 2017, 38 (10) : 758 - 767
  • [10] Phenotypic Differences in Primary Murine Microglia Treated with NOD1, NOD2, and NOD1/2 Agonists
    Wasmuth, Susanne
    Jalilvand, Tida Viola
    Laffer, Bjoern
    Busch, Martin
    Bauer, Dirk
    Langmann, Thomas
    Thanos, Solon
    Kasper, Maren
    Heiligenhaus, Arnd
    [J]. JOURNAL OF MOLECULAR NEUROSCIENCE, 2020, 70 (04) : 600 - 609
12345